Wegovy Shows Significant Heart Disease Benefits, but Experts Caution Off-Label Use

Published on November 16, 2023

A high-profile clinical trial of the obesity drug Wegovy has raised hopes that it may also deliver significant cardiovascular benefits beyond weight loss. The trial, funded by Wegovy’s maker Novo Nordisk, found that the use of the injected drug semaglutide led to a significant reduction in heart attacks, strokes, and cardiovascular deaths among overweight and obese patients with a history of heart disease. “As obesity increases the risk for cardiovascular disease, it is reassuring to see that the [study] showed that semaglutide can help reduce this risk,” Thomas So, who holds a doctorate in pharmacology and is a senior manager of Consumer Drug Information Group at First Databank, told The Epoch Times....

Continue reading on website
Other news

Montreal-Area Mayor Receives Death Threats Over Plan to Cull Deer in Local Park

November 16, 2023
The mayor of a Montreal-area city has allegedly been targeted by death threats in connection with a plan to cull most of the white-tailed deer living in a local park.A spokesman for the City of Longueuil confirmed on Nov. 16 that Mayor Catherine Fournier has been threatened in recent days and weeks by a single individual.Longueuil police Insp. Gino Iannone says the mayor was placed under intermitt

Federal Judge Allows Lawsuit Against Social Media Companies Over Youth Mental Health Crisis

November 16, 2023
A federal judge ruled on Tuesday that Big Tech social media firms must face a lawsuit accusing the companies of designing platforms in a way that creates a “youth mental health crisis.”The multidistrict litigation was brought against Facebook and Instagram (owned by Meta), TikTok (owned by ByteDance), Snapchat, and YouTube (owned by Google). It alleged that the defendants target children as a “cor